Objectives: Adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) therapy has demonstrated promising results in clinical trials. Recognizing the growing potential of cell therapies for solid tumors, oncology services need to prepare for an increasing number of trials and, in the near future, optimize patient access to TIL. Consultation with clinical trials professionals in England, however, highlighted low organizational readiness and significant knowledge gaps for use of adoptive cell therapy. The aim of this discussion paper is to provide guidance about the role of the nurse in the delivery of TIL therapy.
Methods: Guidance was written based on peer-reviewed literature and best practice guidelines between 2006 and 2024 identified through electronic database searches on PubMed, CINAHL, and MEDLINE and expert experience of managing patients in clinical trials who are receiving TIL.
Results: TIL therapy is set to transform current care pathways with treatments that can potentially induce long-lasting tumor responses. There are, however, numerous challenges for successful and safe implementation of TIL therapy in practice. Nurses have a central role in coordinating the safe delivery and patient care of patients receiving TIL therapy. Nurses need knowledge and understanding about the regulatory processes and extensive treatment pathways involved whilst also managing novel side effects and patient expectations.
Conclusions: TIL therapy requires a specialist team to safely deliver these complex treatments and support colleagues nursing patients receiving TIL therapy. Specialist knowledge and skills and close coordination is required to ensure a smooth process from patient referral, product ordering, manufacturing, storage, and administration of the treatment to the patient.
Implications For Nursing Practice: Organizations planning to initiate TIL therapy should review their infrastructure, identify and address specialist knowledge and skills needs of oncology professionals, and seek guidance and support from expert teams. There needs to be a robust governance structure in place and ensure all healthcare professionals involved are trained and educated on a high level on how to care for these patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.soncn.2025.151841 | DOI Listing |
Int J Cosmet Sci
March 2025
Hangzhou Shiguang Xinya Biotechnology Co., Ltd., Hangzhou, China.
Objective: The study investigated effects of peony callus extracts (PCE) on the protective efficacy against Ultraviolet B (UVB)-induced photoageing, using in vitro and in vivo studies. The research focused on PCE's ability to protect against inflammatory factors, DNA damage and accumulation of senescent cells, along with the evaluation of the extract's potential anti-photoageing benefits to skin.
Methods: Human keratinocyte cell line (HaCaT cells), mast cells and fibroblasts were used to evaluate the role of PCE in anti-photoageing.
Future Med Chem
March 2025
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
The rapidly growing interest in the literature about the anticancer activity of 3,5-disubstituted pyrazolines and their promising therapeutic potentials/pharmacological properties, supported by the number of pyrazoline derivatives currently in clinical use or clinical trials, encouraged us to review the antiproliferative effects and biochemical investigations of probable mechanisms of action. Nevertheless, many reported pyrazoline-bearing compounds have anticancer activity without an explored mode of action, which opens new research avenues to examine their biochemical profiles further. Therefore, 3,5-disubstituted pyrazoline is a promising core that can be used to design new derivatives with anticancer activity based on the structure-activity relationship summarized in this review to obtain higher potency and selectivity.
View Article and Find Full Text PDFFront Immunol
March 2025
Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Lung cancer remains a leading cause of cancer-related deaths worldwide, necessitating innovative treatments. Tumor-associated macrophages (TAMs) are primary immunosuppressive effectors that foster tumor proliferation, angiogenesis, metastasis, and resistance to therapy. They are broadly categorized into proinflammatory M1 and tumor-promoting M2 phenotypes, with elevated M2 infiltration correlating with poor prognosis.
View Article and Find Full Text PDFFront Immunol
March 2025
State Key Laboratory of Experimental Hematology, Senior Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Introduction: Older patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. DNA methyltransferases (DNMTs) and histone-deacetylases (HDACs) are key regulators of gene expression in cells and have been investigated as important therapeutic targets. However, their effects remains unclear as induction therapy for AML.
View Article and Find Full Text PDFFront Immunol
March 2025
Department of Orthopaedic Medical Center, The Second Norman Bethune Hospital of Jilin University, Changchun, Jilin, China.
Multiple myeloma (MM) is a malignant disease of plasma cells that accounts for approximately 10% of all hematological malignancies and is characterized by a clonal proliferation of malignant plasma cells in the bone marrow. Numerous therapeutic strategies, including proteasome inhibitors, immunomodulators, monoclonal antibodies against CD38 and autologous stem cell transplantation, have prolonged the median survival of MM patients. Nevertheless, almost all MM patients suffer disease relapses due to drug resistance and eventually die from MM or MM-related complications.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!